Update: Influenza Activity - United States and Worldwide, May 19-September 28, 2019, and Composition of the 2020 Southern Hemisphere Influenza Vaccine
- PMID: 31600182
- PMCID: PMC6788403
- DOI: 10.15585/mmwr.mm6840a3
Update: Influenza Activity - United States and Worldwide, May 19-September 28, 2019, and Composition of the 2020 Southern Hemisphere Influenza Vaccine
Abstract
During May 19-September 28, 2019,* low levels of influenza activity were reported in the United States, with cocirculation of influenza A and influenza B viruses. In the Southern Hemisphere seasonal influenza viruses circulated widely, with influenza A(H3) predominating in many regions; however, influenza A(H1N1)pdm09 and influenza B viruses were predominant in some countries. In late September, the World Health Organization (WHO) recommended components for the 2020 Southern Hemisphere influenza vaccine and included an update to the A(H3N2) and B/Victoria-lineage components. Annual influenza vaccination is the best means for preventing influenza illness and its complications, and vaccination before influenza activity increases is optimal. Health care providers should recommend vaccination for all persons aged ≥6 months who do not have contraindications to vaccination (1).
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. David E. Wentworth reports U.S. patent no. 10,272,149 for a live, synthetic, modified bat influenza virus strain useful for vaccination against a target influenza strain, outside the current work. No other potential conflicts of interest were disclosed.
Figures
Similar articles
-
Update: Influenza Activity - United States and Worldwide, May 20-October 13, 2018.MMWR Morb Mortal Wkly Rep. 2018 Oct 26;67(42):1178-1185. doi: 10.15585/mmwr.mm6742a3. MMWR Morb Mortal Wkly Rep. 2018. PMID: 30359347 Free PMC article.
-
Update: Influenza Activity--United States and Worldwide, May 24-September 5, 2015.MMWR Morb Mortal Wkly Rep. 2015 Sep 18;64(36):1011-6. doi: 10.15585/mmwr.mm6436a4. MMWR Morb Mortal Wkly Rep. 2015. PMID: 26390411
-
Update: Influenza Activity - United States, September 30, 2018-February 2, 2019.MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):125-134. doi: 10.15585/mmwr.mm6806a1. MMWR Morb Mortal Wkly Rep. 2019. PMID: 30763296 Free PMC article.
-
Influenza Activity - United States, 2015-16 Season and Composition of the 2016-17 Influenza Vaccine.MMWR Morb Mortal Wkly Rep. 2016 Jun 10;65(22):567-75. doi: 10.15585/mmwr.mm6522a3. MMWR Morb Mortal Wkly Rep. 2016. PMID: 27281364
-
Update: Influenza Activity - United States, October 1-November 25, 2017.MMWR Morb Mortal Wkly Rep. 2017 Dec 8;66(48):1318-1326. doi: 10.15585/mmwr.mm6648a2. MMWR Morb Mortal Wkly Rep. 2017. PMID: 29216030 Free PMC article.
Cited by
-
In-field detection and characterization of B/Victoria lineage deletion variant viruses causing early influenza activity and an outbreak in Louisiana, 2019.Influenza Other Respir Viruses. 2024 Jan 5;18(1):e13246. doi: 10.1111/irv.13246. eCollection 2024 Jan. Influenza Other Respir Viruses. 2024. PMID: 38188372 Free PMC article.
-
Relative Effectiveness of the Cell-Based Quadrivalent Influenza Vaccine in Preventing Cardiorespiratory Hospitalizations in Adults Aged 18-64 Years During the 2019-2020 US Influenza Season.Open Forum Infect Dis. 2023 Jun 7;10(7):ofad304. doi: 10.1093/ofid/ofad304. eCollection 2023 Jul. Open Forum Infect Dis. 2023. PMID: 37496602 Free PMC article.
-
Hospitalization and risk of death due to influenza among vaccinated and unvaccinated patients. A 5-year study in the northeastern Mexican population.Hum Vaccin Immunother. 2022 Dec 30;18(7):2150474. doi: 10.1080/21645515.2022.2150474. Epub 2022 Dec 1. Hum Vaccin Immunother. 2022. PMID: 36457300 Free PMC article.
-
Relative Effectiveness of Cell-Based Versus Egg-Based Quadrivalent Influenza Vaccines in Adults During the 2019-2020 Influenza Season in the United States.Open Forum Infect Dis. 2022 Oct 12;9(10):ofac532. doi: 10.1093/ofid/ofac532. eCollection 2022 Oct. Open Forum Infect Dis. 2022. PMID: 36320195 Free PMC article.
-
Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.J Virol. 2022 Apr 13;96(7):e0165221. doi: 10.1128/jvi.01652-21. Epub 2022 Mar 15. J Virol. 2022. PMID: 35289635 Free PMC article.
References
-
- Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2019–20 influenza season. MMWR Recomm Rep 2019;68(No. RR-3). 10.15585/mmwr.rr6803a1 - DOI - PMC - PubMed
-
- Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(No. RR-1). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical

